# Rokeya Tasneen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11671552/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 30 papers | 1,771 citations | 430874 18 h-index | 454955 30 g-index |
| 37 all docs | 37 docs citations | 37 times ranked | 1598 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic Lesions. Journal of Infectious Diseases, 2012, 205, 595-602. | 4.0 | 215 |
| 2 | Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2008, 52, 1522-1524. | 3.2 | 203 |
| 3 | Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2011, 55, 5485-5492. | 3.2 | 181 |
| 4 | Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 4331-4340. | 3.2 | 142 |
| 5 | Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 371-376. | 5.6 | 118 |
| 6 | Enhanced Bactericidal Activity of Rifampin and/or Pyrazinamide When Combined with PA-824 in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2008, 52, 3664-3668. | 3.2 | 106 |
| 7 | Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 270-277. | 3.2 | 98 |
| 8 | Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2009, 53, 4178-4184. | 3.2 | 90 |
| 9 | Contribution of the Nitroimidazoles PA-824 and TBA-354 to the Activity of Novel Regimens in Murine Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 129-135. | 3.2 | 75 |
| 10 | Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 68 |
| 11 | Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 62 |
| 12 | Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. Journal of Antimicrobial Chemotherapy, 2010, 65, 729-734. | 3.0 | 49 |
| 13 | Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9. DMM Disease Models and Mechanisms, 2016, 9, 779-88. | 2.4 | 49 |
| 14 | Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 37 |
| 15 | Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 35 |
| 16 | In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. ACS Infectious Diseases, 2017, 3, 492-501. | 3.8 | 33 |
| 17 | In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 2017, 72, 2320-2325. | 3.0 | 30 |
| 18 | Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer. PLoS Neglected Tropical Diseases, 2018, 12, e0006728. | 3.0 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 23 |
| 20 | High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 4197-4205. | 3.2 | 21 |
| 21 | Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 17 |
| 22 | Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 16 |
| 23 | Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. Antimicrobial Agents and Chemotherapy, 2022, 66, e0239821. | 3.2 | 15 |
| 24 | Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 13 |
| 25 | Advancing the Therapeutic Potential of Indoleamides for Tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 12 |
| 26 | GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment. Antimicrobial Agents and Chemotherapy, 2022, 66, . | 3.2 | 12 |
| 27 | Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 570-579. | 5.6 | 10 |
| 28 | Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0025321. | 3.2 | 8 |
| 29 | Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 4 |
| 30 | Reply to â€œContradictory Results with High-Dosage Rifamycin in Mice and Humansâ€• Antimicrobial Agents and Chemotherapy, 2013, 57, 1104-1105. | 3.2 | 3 |